[go: up one dir, main page]

WO1990000594A3 - Vehicules d'expression mycobacteriens de recombinaison et leur utilisation - Google Patents

Vehicules d'expression mycobacteriens de recombinaison et leur utilisation Download PDF

Info

Publication number
WO1990000594A3
WO1990000594A3 PCT/US1989/002962 US8902962W WO9000594A3 WO 1990000594 A3 WO1990000594 A3 WO 1990000594A3 US 8902962 W US8902962 W US 8902962W WO 9000594 A3 WO9000594 A3 WO 9000594A3
Authority
WO
WIPO (PCT)
Prior art keywords
mycobacteria
recombinant
dna
interest
coli
Prior art date
Application number
PCT/US1989/002962
Other languages
English (en)
Other versions
WO1990000594A2 (fr
Inventor
Barry R Bloom
Ronald W Davis
William R Jacobs Jr
Richard A Young
Robert N Husson
Original Assignee
Whitehead Biomedical Inst
Einstein Coll Med
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Biomedical Inst, Einstein Coll Med, Univ Leland Stanford Junior filed Critical Whitehead Biomedical Inst
Priority to DE68929507T priority Critical patent/DE68929507T2/de
Priority to AT89908028T priority patent/ATE256730T1/de
Priority to EP89908028A priority patent/EP0424437B1/fr
Publication of WO1990000594A2 publication Critical patent/WO1990000594A2/fr
Publication of WO1990000594A3 publication Critical patent/WO1990000594A3/fr
Priority to US08/096,027 priority patent/US5591632A/en
Priority to US08/095,734 priority patent/US5807723A/en
Priority to US08/444,623 priority patent/US5866403A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/32—Mycobacterium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des mycobactéries cultivables de recombinaison capables d'exprimer de l'ADN d'intérêt codant au moins un antigène protéique contre lequel on veut obtenir une réponse immune, ainsi que des procédés d'introduction d'ADN d'intérêt dans les mycobactéries. Dans les mycobactéries de recombinaison l'ADN d'intérêt est maintenu stable extrachromosomiquement ou est intégré de manière stable dans de l'ADN génomique. De telles mycobactéries de recombinaison sont utiles comme véhicules servant de vaccins pour assurer l'immunité contre un gène pathogène, de ''vaccins'' anti-fécondité, et pour augmenter non spécifiquement des réponses immunitaires à des antigènes étrangers exprimés par BCG ou pour traiter des cancers chez l'homme. L'invention concerne également des vecteurs de recombinaison utiles pour introduire de l'ADN d'intérêt dans des mycobactéries, où il est exprimé. Un type de vecteur est un plasmide de recombinaison capable de réplication en tant que plasmide dans E. coli, et de lysogérer un hôte mycobactérien. Un second type de vecteur est un plasmide de recombinaison que l'on peut introduire dans des mycobactéries, où il est maintenu stable extrachromosomiquement. Un troisième type de vecteur de recombinaison est du type à réplication dans E. coli mais pas dans des mycobactéries. Il comprend: 1) un gène ou des sections de gène mycobactérien, requis pour la recombinaison avec des séquences homologues dans le génome des mycobactéries transformées à l'aide du plasmide de recombinaison; 2) tout ou une partie d'un gène en codant un polypeptide ou une protéine dont on veut obtenir l'expression dans des mycobactéries transformées à l'aide du plasmide de recombinaison; 3) des séquences d'ADN nécessaires à la réplication et à la sélection dans E. coli et 4) des séquences d'ADN nécessaires à la sélection dans des mycobactéries (par exemple, résistance aux médicaments).
PCT/US1989/002962 1987-03-02 1989-07-07 Vehicules d'expression mycobacteriens de recombinaison et leur utilisation WO1990000594A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE68929507T DE68929507T2 (de) 1988-07-07 1989-07-07 Rekombinante mykobakterielle expressions-träger sowie deren verwendung
AT89908028T ATE256730T1 (de) 1988-07-07 1989-07-07 Rekombinante mykobakterielle expressions-träger sowie deren verwendung
EP89908028A EP0424437B1 (fr) 1988-07-07 1989-07-07 Vehicules d'expression mycobacteriens de recombinaison et leur utilisation
US08/096,027 US5591632A (en) 1987-03-02 1993-07-22 Recombinant BCG
US08/095,734 US5807723A (en) 1987-03-02 1993-07-22 Homologously recombinant slow growing mycobacteria and uses therefor
US08/444,623 US5866403A (en) 1987-03-02 1995-05-19 Homologously recombinant slow growing mycobacteria and uses therefor

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US21639088A 1988-07-07 1988-07-07
US216,390 1988-07-07
US22308988A 1988-07-22 1988-07-22
US223,089 1988-07-22
US07/361,944 US5504005A (en) 1987-03-02 1989-06-05 Recombinant mycobacterial vaccine
US361,944 1989-06-05

Publications (2)

Publication Number Publication Date
WO1990000594A2 WO1990000594A2 (fr) 1990-01-25
WO1990000594A3 true WO1990000594A3 (fr) 1990-05-03

Family

ID=27396269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/002962 WO1990000594A2 (fr) 1987-03-02 1989-07-07 Vehicules d'expression mycobacteriens de recombinaison et leur utilisation

Country Status (8)

Country Link
US (5) US5504005A (fr)
EP (1) EP0424437B1 (fr)
JP (2) JP3485916B2 (fr)
AT (1) ATE256730T1 (fr)
AU (1) AU3867789A (fr)
CA (1) CA1339526C (fr)
DE (1) DE68929507T2 (fr)
WO (1) WO1990000594A2 (fr)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807723A (en) * 1987-03-02 1998-09-15 Whitehead Institute For Biomedical Research Homologously recombinant slow growing mycobacteria and uses therefor
JP2903414B2 (ja) * 1989-05-31 1999-06-07 味の素株式会社 抗酸菌分泌発現ベクター及び抗酸菌
EP0400973B1 (fr) * 1989-05-31 1996-07-31 Ajinomoto Co., Inc. Vecteurs d'expression et de sécrétion pour mycobacterium et les transformants
JPH04506297A (ja) * 1989-06-19 1992-11-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ ベクター媒介ゲノム挿入及びｂｃｇにおけるｄｎａの発現
EP0517751A4 (en) * 1990-02-26 1993-03-31 Commonwealth Scientific & Industrial Research Organisation ( C.S.I.R.O. ) Shuttle plasmid for escherichia coli and mycobacteria
CA2045842A1 (fr) * 1990-07-16 1992-01-17 William R. Jacobs Adn capable de s'integrer dans un site particulier de mycobacteries
GB9015888D0 (en) * 1990-07-19 1990-09-05 Smithkline Biolog Vectors
AU643842B2 (en) * 1990-10-25 1993-11-25 Commonwealth Scientific And Industrial Research Organisation Corynebacteria and related organisms as vaccine vectors
US5637303A (en) * 1990-10-25 1997-06-10 Commonwealth Scientific And Industrial Research Organisation Use of a phospholipase D mutant of Corynebacterium pseudotuberculosis for vaccination
JPH06501847A (ja) * 1990-10-25 1994-03-03 コモンウェルス　サイエンティフィク　アンド　インダストリアルリサーチ　オーガナイゼイション ワクチンベクターとしてのコリネバクテリウム及び関連する生物
AU2221992A (en) * 1991-06-06 1993-01-08 Med Immune, Inc. Induction of immune response against tetanus toxin through administration of mycobacteria expressing tetanus toxin or fragments
CA2110682A1 (fr) * 1991-06-06 1992-12-10 Charles K. Stover Induction des reponses des ctl aux antigenes etrangers exprimes dans les mycobacteries
US6566121B1 (en) 1991-06-13 2003-05-20 Albert Einstein College Of Medicine Of Yeshiva University Insertional mutations in mycobacteria
AU2189392A (en) * 1991-06-13 1993-01-12 Albert Einstein College Of Medicine Of Yeshiva University Insertional mutations in mycobacteria
EP0521220A1 (fr) 1991-06-14 1993-01-07 Institut Pasteur Actinomycétale immunogène recombinant
US5750384A (en) * 1992-02-07 1998-05-12 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University L5 shuttle phasmids
US6300061B1 (en) 1992-02-07 2001-10-09 Albert Einstein College Of Medicine Of Yeshiva University Mycobacterial species-specific reporter mycobacteriophages
US5330754A (en) * 1992-06-29 1994-07-19 Archana Kapoor Membrane-associated immunogens of mycobacteria
US7063844B2 (en) 1992-12-10 2006-06-20 The Brigham And Women's Hospital, Inc. Presentation of hydrophobic antigens to T-cells by CD1 molecules
US6238676B1 (en) 1992-12-10 2001-05-29 Brigham And Women's Hospital Presentation of hydrophobic antigens to T-cells by CD1 molecules
ATE212378T1 (de) * 1993-06-04 2002-02-15 Whitehead Biomedical Inst Stressproteine und ihre verwendung
ATE407945T1 (de) 1993-11-23 2008-09-15 Univ California Reichlich vorhandene extrazelluläre produkte und methoden zu ihrer herstellung sowie ihre verwendung
US6752993B1 (en) 1993-11-23 2004-06-22 The Regents Of The University Of California Abundant extracellular product vaccines and methods for their production and use
US7300660B2 (en) 1993-11-23 2007-11-27 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
FR2720076B1 (fr) 1994-05-20 1996-08-02 Inst Nat Sante Rech Med Vecteurs navettes pour l'introduction d'ADN dans des mycobactéries et utilisation de ces bactéries comme vaccins.
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
AU774535B2 (en) * 1995-10-20 2004-07-01 Actogenix Nv Delivery of biologically active polypeptides
US6013660A (en) * 1996-10-02 2000-01-11 The Regents Of The University Of California Externally targeted prophylactic and chemotherapeutic method and agents
US6221364B1 (en) * 1996-11-12 2001-04-24 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacteria auxotrophic for diaminopimelate
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
ATE382368T1 (de) * 1997-01-21 2008-01-15 Univ California Epitopen eines extrazellulären antigens
EP1047451A1 (fr) * 1997-02-18 2000-11-02 Whitehead Institute For Biomedical Research Utilisation de proteines de choc thermique pour introduire des fractions dans des cellules
US7087713B2 (en) * 2000-02-25 2006-08-08 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
EP1002110B2 (fr) * 1997-08-05 2009-07-29 Stressgen Biotechnologies Corporation Reponses immunitaires contre les antigenes du vph et declenchees par des compositions comprenant un antigene du vph, et proteine du stress ou vecteur d'expression capable d'exprimer ces proteines
AU3710597A (en) 1997-08-06 1999-03-01 Laboratorio Medinfar-Produtos Farmaceuticos, Lda Dna integration into "mycobacterium spp." genome by trans-complementation using a site-specific integration system
US6322991B1 (en) * 1997-08-21 2001-11-27 York University High-throughput screens for enzyme inhibitors
EP0902086A1 (fr) * 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccin contre la tubercolose
US5972700A (en) * 1997-09-26 1999-10-26 Albert Einstein College Of Medicine Of Yeshiva University TM4 conditional shuttle phasmids and uses thereof
US6387694B1 (en) 1998-04-03 2002-05-14 Albert Einstein College Of Medicine Of Yeshiva University Mycobacterial isocitrate lyase gene and uses thereof
CA2340330A1 (fr) 1998-08-20 2000-03-02 Aventis Pasteur Limited Molecules d'acide nucleique codant la proteine membrane d'inclusion c de chlamydia
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6497880B1 (en) * 1998-12-08 2002-12-24 Stressgen Biotechnologies Corporation Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
WO2000047227A2 (fr) * 1999-02-09 2000-08-17 Powderject Vaccines, Inc. IMMUNISATION CONTRE $i(MYCOBACTERIUM TUBERCULOSIS)
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
CN1367875A (zh) * 1999-07-08 2002-09-04 斯特思吉生物技术公司 活体外th1一样反应的诱导方法
JP2003510370A (ja) * 1999-10-07 2003-03-18 コリクサ コーポレイション Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓの融合タンパク質
ES2306670T3 (es) 1999-10-22 2008-11-16 Sanofi Pasteur Limited Procedimiento de induccion y/o intensificacion de la respuesta inmunitaria frente a antigenos tumorales.
DE60042704D1 (de) 2000-01-14 2009-09-17 Whitehead Biomedical Inst Induktion zytotoxischer lymphozyten durch hitzeschockprotein-fusionsproteine hängt von der atp-bindungsdomäne in hsp ab und is cd4+ unabhängig
US6924118B2 (en) * 2000-04-17 2005-08-02 The Regents Of The University Of California Recombinant intracellular pathogen immunogenic compositions and methods for use
US6471967B1 (en) 2000-04-17 2002-10-29 The Regents Of The University Of California Recombinant intracellular pathogen vaccines and methods for use
EP1792995A3 (fr) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Antigènes de chlamydia et fragments d'adn correspondants, et utilisations de ceux-ci
EP1741782B1 (fr) * 2000-05-10 2011-06-22 Sanofi Pasteur Limited Polypeptides immunogéniques codés par des minigènes mage et leurs utilisations
DE60139963D1 (de) * 2000-06-20 2009-10-29 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
PL359930A1 (en) 2000-06-26 2004-09-06 Stressgen Biotechnologies Corporation Human papilloma virus treatment
DE60127421T8 (de) 2000-08-25 2008-08-28 Chancellor, Masters And Scholars Of The University Of Oxford Innen-kern oligosaccharide epitopes aus lipopolysacchariden von haemophilus influenza als vakzinen in der prophylaktischen behandlung von haemophilus influenzae infektionen
US7060462B2 (en) 2000-11-02 2006-06-13 National University Of Singapore AopB gene, protein,homologs, fragments and variants thereof, and their use for cell surface display
IL157251A0 (en) * 2001-02-05 2004-02-19 Stressgen Biotechnologies Corp Hepatitis b virus treatment
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US7396822B2 (en) * 2001-05-24 2008-07-08 Vaxiion Therapeutics, Inc. Immunogenic minicells and methods of use
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
US7026465B2 (en) 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
US7758874B2 (en) * 2002-02-19 2010-07-20 Albert Einstein College Of Medicine Of Yeshiva University Attenuated Mycobacterium tuberculosis vaccines
US7722861B2 (en) * 2002-02-19 2010-05-25 Svetoslav Bardarov, legal representative Attenuated Mycobacterium tuberculosis vaccines
US7074559B2 (en) * 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
DE60315628T2 (de) 2002-04-09 2008-06-05 Sanofi Pasteur Ltd., Toronto Modifizierte cea nucleinsäure und expressionsvektoren
RU2339692C2 (ru) * 2002-04-16 2008-11-27 Цзюнь ЛЮ Туберкулезные вакцины, содержащие рекомбинантные штаммы бцж, экспрессирующие аланиндегидрогеназу, сериндегидратазу и/или глютаминсинтетазу
WO2004001020A2 (fr) * 2002-06-19 2003-12-31 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Procedes et moyens permettant de favoriser l'absorption intestinale
DE60322070D1 (de) * 2002-08-16 2008-08-21 Dept Of Medical Sciences Minis Rekombinante bcg-vakzine
EP1560935A2 (fr) * 2002-11-15 2005-08-10 VIB vzw Souche de lactobacillus autonome
ES2347239T3 (es) * 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
WO2004066928A2 (fr) * 2003-01-24 2004-08-12 Albert Einstein College Of Medicine Of Yeshiva University Utilisation de vaccins a mycobacteries chez des mammiferes presentant une deficience en lymphocytes cd4+ et/ou cd8+.
JP4668919B2 (ja) * 2003-10-08 2011-04-13 サノフィ パストゥール インコーポレイテッド 修飾ｃｅａ／ｂ７ベクター
US8287879B2 (en) * 2003-10-16 2012-10-16 The Regents Of The University Of California Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
WO2007121193A1 (fr) * 2006-04-10 2007-10-25 The Regents Of The University Of California Compositions immunogènes à agents pathogènes intracellulaires recombinés à croissance régulable, et procédés d'utilisation
DK2206514T3 (da) 2003-10-16 2014-04-22 Univ California Rekombinante intracellulære patogene immunogene sammensætninger og metoder til anvendelse
US8383132B2 (en) * 2003-10-16 2013-02-26 The Regents Of The University Of California Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
WO2006055024A2 (fr) * 2004-04-05 2006-05-26 Vaxiion Therapeutics, Inc. Minicellules employees comme vaccins
US7998471B2 (en) * 2005-01-12 2011-08-16 Albert Einstein College Of Medicine Of Yeshiva University Mycobacteria expressing HIV-1 and malaria antigens
AU2006204907B2 (en) * 2005-01-12 2011-08-11 Albert Einstein College Of Medicine, Inc. Mycobacterial mutants affecting host apoptosis
AU2006206851B2 (en) 2005-01-18 2010-12-16 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Mycobacteria with mannose cap-deficient lipoarabinomannan
JP2009502747A (ja) * 2005-07-14 2009-01-29 ビーエーエスエフ ソシエタス・ヨーロピア １−メチル−ピラゾール−４−イルカルボキシアニリド類に基づく殺菌性混合物
EP2119450B1 (fr) 2005-11-29 2013-02-13 Actogenix N.V. Induction de tolérance antigénique mucosale pour des auto-antigènes de cellules d'îlot pancréatiques
WO2007067729A2 (fr) * 2005-12-09 2007-06-14 University Of Georgia Research Foundation, Inc. Vaccin microbien et vecteur de vaccin
CN101395265B (zh) * 2006-01-12 2013-06-12 犹太大学阿尔伯特爱因斯坦医学院 分枝杆菌SecA2突变体
ES2492468T3 (es) 2007-01-25 2014-09-09 Actogenix N.V. Tratamiento de enfermedad inmunitaria por administración a través de la mucosa de antígenos usando Lactobacillus genéticamente modificado
US8591918B2 (en) 2007-03-19 2013-11-26 Albert Einstein College Of Medicine Of Yeshiva University Mycobacterial mutants inducing IL-12
KR101445903B1 (ko) 2007-05-02 2014-09-29 메리얼 리미티드 향상된 발현 및 안정성을 갖는 ｄｎａ 플라스미드
US7670609B2 (en) * 2007-11-27 2010-03-02 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to Mycobacterium tuberculosis in all physiological stages of infection and disease
US8361482B2 (en) * 2007-11-27 2013-01-29 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to mycobacterium tuberculosis in all physiological stages of infection and disease
RU2392002C2 (ru) * 2008-04-02 2010-06-20 ФГОУ ВПО Курская государственная сельскохозяйственная академия им. профессора И.И. Иванова Способ получения туберкулезного анатоксина
RU2372936C1 (ru) * 2008-05-19 2009-11-20 Закрытое акционерное общество "Томские клеточные технологии" (ЗАО "Томские клеточные технологии") Способ получения аутологичной вакцины для лечения туберкулеза
US8758766B2 (en) 2008-12-24 2014-06-24 The Kingdom of The Netherlands, Represented by The Mininster of Health, Welfare and Sport, on Behalf of The Minster The National Institute of Public Health and The Environment Modified Streptococcus pneumoniae pneumolysin (PLY) polypeptides
WO2012101509A2 (fr) 2011-01-28 2012-08-02 Sanofi Pasteur Sa Compositions immunologiques contre le vih
JP6199746B2 (ja) 2011-02-15 2017-09-20 バキシオン セラピューティクス，リミテッド ライアビリティ カンパニー 抗体およびＦｃ含有標的化分子に基づく生理活性分子の標的送達のための細菌ミニ細胞による治療用組成物および方法
JP6193231B2 (ja) 2011-08-08 2017-09-06 チュアラボ オンコロジー, インコーポレーテッドCurelab Oncology, Inc. がんの治療および予防のための、ｐ６２に関する方法および組成物
WO2013059616A1 (fr) * 2011-10-21 2013-04-25 Albert Einstein College Of Medicine Of Yeshiva University Mycobactériophages recombinants permettant d'administrer des acides nucléiques d'intérêt dans des mycobactéries
BR102012003790A2 (pt) 2012-02-17 2014-04-22 Fundacao Butantan Cepa de mycobacterium recombinante, composição imunogênica e uso
WO2014032835A1 (fr) 2012-08-31 2014-03-06 Laboratorios Del Dr. Esteve, S.A. Mycobactérie comprenant un vecteur d'expression doté de deux marqueurs de sélection auxotrophiques et son utilisation comme vaccin
WO2014041189A1 (fr) 2012-09-17 2014-03-20 Novartis Ag Alphavirus de salmonidé et ses utilisations
EP2914618B1 (fr) 2012-11-02 2017-07-26 Novartis Tiergesundheit AG Flavivirus associés à la maladie de theiler
WO2014140938A2 (fr) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Méthodes immunologiques
WO2015100446A1 (fr) 2013-12-29 2015-07-02 Curelab Oncology, Inc. Méthodes et compositions relatives à p62/sqstm1 pour traiter et prévenir les maladies associées à une inflammation
AU2015298356B2 (en) 2014-08-05 2020-11-19 MabQuest SA Immunological reagents binding to pd-1
EP3383902A1 (fr) 2015-12-05 2018-10-10 Centre Hospitalier Universitaire Vaudois Agents de liaison au vih
DK3964529T3 (da) 2016-01-22 2025-06-30 MabQuest SA Ikke-blokerende pd1-specifikke antistoffer
CN109312409A (zh) * 2016-03-31 2019-02-05 金山大学,约翰内斯堡 耻垢分枝杆菌的遗传修饰株
WO2018002940A1 (fr) * 2016-06-30 2018-01-04 Technology Innovation Momentum Fund (Israel) Limited Partnership Variants de bactériophages présentant une gamme d'hôtes étendue, procédés de préparation et utilisations correspondants dans la transduction d'acides nucléiques dans des hôtes d'intérêt
CN111511907A (zh) 2017-03-14 2020-08-07 加利福尼亚大学董事会 对病毒中免疫逃逸功能区域的全基因组鉴定
CN109825497A (zh) * 2019-01-25 2019-05-31 石河子大学 一种新型结核杆菌融合菌株的制备方法及其应用
US20220267416A1 (en) 2019-07-15 2022-08-25 Lausanne University Hospital Hiv binding agents
TWI884296B (zh) 2020-08-11 2025-05-21 美商碩騰服務公司 抗冠狀病毒疫苗
CN114315985A (zh) 2020-09-29 2022-04-12 硕腾服务有限责任公司 减毒猪流行性腹泻病毒
WO2022203308A1 (fr) * 2021-03-22 2022-09-29 클립스비엔씨 주식회사 Nouvelle souche recombinée de mycobacterium smegmatis et son utilisation
CA3230802A1 (fr) 2021-08-31 2023-03-09 Zoetis Services Llc Alphavirus attenue

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127328A2 (fr) * 1983-04-28 1984-12-05 Genex Corporation L'emploi d'une intégration dans des chromosomes pour stabiliser des gènes hétérologues
EP0191643A2 (fr) * 1985-02-13 1986-08-20 Biotechnica International, Inc. Intégration d'un gène dans un chromosome et découpage contrôlé de celui-ci
WO1988000974A2 (fr) * 1986-07-31 1988-02-11 Whitehead Institute For Biomedical Research Genes de codage d'antigenes de m. leprae
WO1988006626A1 (fr) * 1987-03-02 1988-09-07 Whitehead Institute For Biomedical Research Vaccin mycobacterien recombinant

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8314645D0 (en) * 1983-05-26 1983-06-29 Wellcome Found Bivalent vaccines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127328A2 (fr) * 1983-04-28 1984-12-05 Genex Corporation L'emploi d'une intégration dans des chromosomes pour stabiliser des gènes hétérologues
EP0191643A2 (fr) * 1985-02-13 1986-08-20 Biotechnica International, Inc. Intégration d'un gène dans un chromosome et découpage contrôlé de celui-ci
WO1988000974A2 (fr) * 1986-07-31 1988-02-11 Whitehead Institute For Biomedical Research Genes de codage d'antigenes de m. leprae
WO1988006626A1 (fr) * 1987-03-02 1988-09-07 Whitehead Institute For Biomedical Research Vaccin mycobacterien recombinant

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTACTS, Vol. 96, No. 19, 10 May 1982, (Columbus, Ohio, US), S. BRENNER et al.: "Phasmids: Hybrids Between Co1E1 Plasmids and E. Coli Bacteriophage Lambda", page 187* Abstact No. 156476C, & Gene 1982, 17(1), 27-44* *
Infection and Immunity, Vol. 52, No. 1, April 1986, American Society for Microbiology, W.R. JACOBS et al.: "in Vivo Repack-Aging of Recombinant Cosmid Molecules for Analyses of Salmonella Typhimurium, Streptococcus Mutants, and Mycobacterial Genomic Libraries", pages 101-109 *
Nature, Vol. 327, No. 6122, 11-17 June 1987, (Basingstoke, Hampshire, GB), W.R. Jacobs, Jr. et al.: "Introduction of Foreign DNA into Mycobacteria Using a Shuttle Phasmid", pages 532-535 *
Proc. Natl. Acac. Sci. USA, Vol. 85, September 1988, S.B. SNAPPER et al.: "Lysogeny and Transformation in Mycobacteria: Stable Expression of Foreign Genes", pages 6987-6991, *
Reviews of Infectious Diseases, Vol. II, Supplement 2, March-April 1989, The University of Chicago, W.R. JACOBS, JR. et al.: "Mycobacteriophage Vector Systems", pages 404-410 *

Also Published As

Publication number Publication date
AU3867789A (en) 1990-02-05
JP3485916B2 (ja) 2004-01-13
JPH04500305A (ja) 1992-01-23
JP2000350578A (ja) 2000-12-19
ATE256730T1 (de) 2004-01-15
US6270776B1 (en) 2001-08-07
US5968733A (en) 1999-10-19
WO1990000594A2 (fr) 1990-01-25
EP0424437B1 (fr) 2003-12-17
EP0424437A1 (fr) 1991-05-02
US5854055A (en) 1998-12-29
DE68929507D1 (de) 2004-01-29
DE68929507T2 (de) 2004-09-23
CA1339526C (fr) 1997-11-04
US6372478B1 (en) 2002-04-16
US5504005A (en) 1996-04-02

Similar Documents

Publication Publication Date Title
WO1990000594A3 (fr) Vehicules d'expression mycobacteriens de recombinaison et leur utilisation
DE3854840D1 (de) Rekombinant-mykobakterielle impfstoffe
AU5848090A (en) Vector-mediated genomic insertion and expression of dna in bcg
WO1996040915A3 (fr) Nouveaux ligands de ctla4/cd28 et leurs utilisations
EP1363660A4 (fr) Vaccin moleculaire superieur a base d'arn autoreplicatif, d'adn suicide ou de vecteur d'adn nu, qui lie un antigene a un polypeptide qui favorise la presentation de l'antigene
WO2001072976A3 (fr) 32142, 21481, 25964, 21686, nouvelles molecules deshydrogenases humaines et utilisations
WO2001096392A3 (fr) Molecules 22109, constituant un nouveau membre de la famille des thioredoxines humaines et utilisations correspondantes
AU2001280639A1 (en) 13237,18480,2245 or 16228 human protein kinase molecules and uses therefor
WO2002026803A3 (fr) 22108 et 47916, nouveaux membres de la famille des thioredoxines humaines et leurs applications
AU2001249649A1 (en) 16836, a novel human phospholipase c family member and uses thereof
WO2002018556A3 (fr) 8797, nouvelle galactosyltransferase humaine et ses applications
AU2001251410A1 (en) 12303, a novel human twik molecule and uses thereof
WO2002024743A3 (fr) 55063, nouveau membre de la famille nmda humaine et ses applications
WO2002020801A3 (fr) 26199, 33530, 33949, 47148, 50226, et 58764, nouveaux membres de la famille des transferases humaines et utilisations de ceux-ci
WO2002016562A3 (fr) 22244 et 8701, nouvelles deshydrogenases humaines et leurs utilisations
WO2002016568A3 (fr) 46863, methyltransferase humaine, et utilisations
AU2002352068A1 (en) 2150, a human protein kinase family member and uses therefor
WO2002006326A3 (fr) 62088, un nouveau membre humain de la famille nucleoside phosphatase, et utilisations de ce dernier
WO2002059314A3 (fr) 52020, nouvel antigene associe a un melanome humain et ses utilisations
WO2002002761A3 (fr) 57658, nouvelle uridine kinase humaine et utilisations correspondantes
AU2002359572A1 (en) 15603, a human ion channel family member
WO2001081559A3 (fr) 26335, serine/threonine dehydratase humaine et ses utilisations
WO2002088357A3 (fr) Nouvelles proteines humaines 84242, 8035, 55304, 52999 et 21999 et procedes de production desdites proteines
WO2001081586A3 (fr) 21657, deshydrogenase humaine a chaine courte et ses utilisations
WO2002026983A3 (fr) 56115, nouveau canal potassium humain associe a twik et applications de celui-ci

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR DK FI HU JP NO RO SU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR DK FI HU JP NO RO SU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989908028

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989908028

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1989908028

Country of ref document: EP